Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER ⁺ breast cancer.

Autor: Gawrzak S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Rinaldi L; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Gregorio S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Arenas EJ; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Salvador F; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Urosevic J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Figueras-Puig C; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Rojo F; CIBERONC, Madrid, Spain.; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain., Del Barco Barrantes I; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Cejalvo JM; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain., Palafox M; Experimental Therapeutics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain., Guiu M; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Berenguer-Llergo A; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Symeonidi A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Bellmunt A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Kalafatovic D; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Arnal-Estapé A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; Department of Pathology, Yale University School of Medicine, Yale, CT, USA., Fernández E; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Müllauer B; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Groeneveld R; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Slobodnyuk K; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Stephan-Otto Attolini C; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain., Saura C; Department of Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain.; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Arribas J; CIBERONC, Madrid, Spain.; Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Universitat Autònoma de Barcelona, Bellaterra, Spain.; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain., Cortes J; Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Ramon y Cajal University Hospital, Madrid, Spain., Rovira A; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Medical Oncology Service, Hospital del Mar, Barcelona, Spain., Muñoz M; Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain.; Department of Oncology, Hospital Clinic de Barcelona, Barcelona, Spain., Lluch A; CIBERONC, Madrid, Spain.; Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain.; University of Valencia, Valencia, Spain.; INCLIVA, Instituto de Investigación Sanitaria, Valencia, Spain., Serra V; CIBERONC, Madrid, Spain.; Experimental Therapeutics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain., Albanell J; CIBERONC, Madrid, Spain.; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Medical Oncology Service, Hospital del Mar, Barcelona, Spain.; Universitat Pompeu Fabra, Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain.; Department of Oncology, Hospital Clinic de Barcelona, Barcelona, Spain., Nebreda AR; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain., Benitah SA; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain., Gomis RR; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain. roger.gomis@irbbarcelona.org.; CIBERONC, Madrid, Spain. roger.gomis@irbbarcelona.org.; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. roger.gomis@irbbarcelona.org.; Universitat de Barcelona, Barcelona, Spain. roger.gomis@irbbarcelona.org.

Publikováno v: Nature cell biology [Nat Cell Biol] 2018 Aug; Vol. 20 (8), pp. 990.